Deutsche Bank’s Cascadian Therapeutics CASC Stock Holding History
Bought
Maintained
Sold
Other funds holding CASC
SH
Deutsche Bank's CASC Position: Q4 2017 in Review
Deutsche Bank reduced its Cascadian Therapeutics (CASC) stake by 75% in Q4 2017, selling an estimated $1M and leaving 81,083 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #3838.
Deutsche Bank first reported a position in CASC in Q2 2013 and has held it in 19 quarters since. The position peaked at $1.99M in Q2 2015. 91 funds tracked by Wall St. Rank hold CASC as of Q4 2017.
- Deutsche Bank held 81,083 shares of Cascadian Therapeutics worth $299K as of Q4 2017.
- Deutsche Bank sold 244,491 Cascadian Therapeutics shares in Q4 2017, an estimated $1M.
- Cascadian Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q4 2017, its #3838 holding.
- Deutsche Bank first reported a position in Cascadian Therapeutics in Q2 2013 and has held it in 19 quarters since.
- Deutsche Bank's Cascadian Therapeutics position peaked at $1.99M in Q2 2015.
- 91 funds tracked by Wall St. Rank held Cascadian Therapeutics as of Q4 2017.
Based on Deutsche Bank's 13F filing for Q4 2017, filed 14 Feb 2018.